Imexpharm Corporation at its Board Meeting held on January 03, 2017, approved the estimated business result in 2016: total revenue of VND 1,005 billion, equivalent to 91% of plan for 2016 and profit before tax & extract from Science and Technology Fund of VND 137 billion, equivalent to 98% of plan for 2016. The company expects business production in 2017: total revenue of VND 1,260 billion, increase 25% compare with the 2016 and profit before tax & extract from Science and Technology Fund of VND 160 billion, increase 17% compare with the 2016.